cd19 car‑t infusion steps
Track 30% Gains in Chronic Disease Management Using CD19
In the CASTLE trial, 27% of patients developed optic neuritis within six months, yet CD19 CAR-T therapy still yields up to 30% overall gains in chronic disease management by reshaping immune pathways. This comes as clinicians combine the cell product with proactive multidisciplinary care, turning a high-risk procedure into a